Listed

Grace Therapeutics, Inc.: Form 20-F for the period ended Mar 31, 2018

Filed with the SEC on Jun 29, 2018 and accepted by EDGAR at Jun 29, 2018, 11:35 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income12 months2017-04-01 to 2018-03-31−CAD 19.7mifrs-full:ProfitLossFromOperatingActivities
Net income12 months2017-04-01 to 2018-03-31−CAD 21.5mifrs-full:ProfitLoss
Operating cash flow12 months2017-04-01 to 2018-03-31−CAD 12.5mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2017-04-01 to 2018-03-31CAD 455.0kifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2018-03-31CAD 8.2mifrs-full:CashAndCashEquivalents
Current assetsAt period end2018-03-31CAD 9.5mifrs-full:CurrentAssets
Total assetsAt period end2018-03-31CAD 23.0mifrs-full:Assets
Current liabilitiesAt period end2018-03-31CAD 6.7mifrs-full:CurrentLiabilities
Total liabilitiesAt period end2018-03-31CAD 14.7mifrs-full:Liabilities
Shares outstandingAt period end2018-03-3125,638,215 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001171843-18-004911. Last ingested by Listed: Nov 14, 2026, 23:10 ET. Listed shows no prices and gives no investment advice.